[go: up one dir, main page]

HRP20100395T1 - Cjepivo protiv tuberkuloze poboljšane učinkovitosti - Google Patents

Cjepivo protiv tuberkuloze poboljšane učinkovitosti Download PDF

Info

Publication number
HRP20100395T1
HRP20100395T1 HR20100395T HRP20100395T HRP20100395T1 HR P20100395 T1 HRP20100395 T1 HR P20100395T1 HR 20100395 T HR20100395 T HR 20100395T HR P20100395 T HRP20100395 T HR P20100395T HR P20100395 T1 HRP20100395 T1 HR P20100395T1
Authority
HR
Croatia
Prior art keywords
cell
cell according
domain
nucleic acid
polypeptide
Prior art date
Application number
HR20100395T
Other languages
English (en)
Croatian (hr)
Inventor
Grode Leander
H. Stefan
Raupach B�rbel
Hess J�rgen
Original Assignee
Max-Planck-Gesellschaft Zur Frderung Der Wissenschaften E.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max-Planck-Gesellschaft Zur Frderung Der Wissenschaften E.V. filed Critical Max-Planck-Gesellschaft Zur Frderung Der Wissenschaften E.V.
Publication of HRP20100395T1 publication Critical patent/HRP20100395T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HR20100395T 2003-04-23 2004-04-23 Cjepivo protiv tuberkuloze poboljšane učinkovitosti HRP20100395T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23
PCT/EP2004/004345 WO2004094469A1 (en) 2003-04-23 2004-04-23 Tuberculosis vaccine with improved efficacy

Publications (1)

Publication Number Publication Date
HRP20100395T1 true HRP20100395T1 (hr) 2010-09-30

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100395T HRP20100395T1 (hr) 2003-04-23 2004-04-23 Cjepivo protiv tuberkuloze poboljšane učinkovitosti

Country Status (23)

Country Link
US (2) US7988980B2 (uk)
EP (1) EP1618128B1 (uk)
JP (1) JP4662925B2 (uk)
KR (1) KR101101263B1 (uk)
CN (1) CN1798762B (uk)
AT (1) ATE473238T1 (uk)
AU (1) AU2004232485B2 (uk)
BR (1) BRPI0409789B8 (uk)
CA (1) CA2523084C (uk)
CU (1) CU23608A3 (uk)
CY (1) CY1110793T1 (uk)
DE (1) DE602004028000D1 (uk)
DK (1) DK1618128T3 (uk)
ES (1) ES2344698T3 (uk)
HR (1) HRP20100395T1 (uk)
MX (1) MXPA05011360A (uk)
PL (1) PL1618128T3 (uk)
PT (1) PT1618128E (uk)
RU (1) RU2342400C2 (uk)
SI (1) SI1618128T1 (uk)
UA (1) UA91180C2 (uk)
WO (1) WO2004094469A1 (uk)
ZA (1) ZA200508276B (uk)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004028000D1 (de) * 2003-04-23 2010-08-19 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
ES2366622T3 (es) 2004-12-01 2011-10-24 Aeras Global Tb Vaccine Foundation Cepas de bcg recombinante con capacidad potenciada para escapar del endosoma.
EP2818178A1 (en) * 2008-01-11 2014-12-31 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Polypeptide vaccine and vaccination strategy against mycobacterium
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
BR112013004389A2 (pt) 2010-08-27 2016-05-17 Pantarhei Bioscience Bv método imunoterapêutico para tratamento do câncer de próstata
KR101907222B1 (ko) * 2010-09-20 2018-10-11 바크지네 프로제크트 마나게멘트 게엠베하 인간에게 사용하기 위한 백신으로서 재조합 마이코박테리움
PL2638062T3 (pl) 2010-11-10 2018-11-30 Laboratorios Leti, S.L. Nowy adiuwant
KR101832019B1 (ko) 2010-12-21 2018-02-23 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 백신으로서의 재조합 마이코박테리움
SG191331A1 (en) * 2010-12-21 2013-07-31 Max Planck Gesellschaft Determination of the efficacy of an anti-mycobacterial vaccination
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
US20180256633A1 (en) 2015-09-18 2018-09-13 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
US11717565B2 (en) * 2017-04-07 2023-08-08 Chengdu Anyong Dingye Biotechnology Co., Ltd. Recombinant BCG overexpressing phoP-phoR
WO2019021064A1 (en) * 2017-07-25 2019-01-31 Aurora Labs Ltd CONSTRUCTION OF SOFTWARE DELTA UPDATES FOR VEHICLE ECU SOFTWARE AND TOOL-BASED ANOMALY DETECTION
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
EP4149529A1 (en) 2020-05-11 2023-03-22 Vakzine Projekt Management GmbH Prevention of infectious diseases by modulating the immune system
JPWO2022075458A1 (uk) * 2020-10-09 2022-04-14
MX2024000980A (es) 2021-07-22 2024-06-21 Serum Life Science Europe Gmbh Mycobacterium recombinante como un agente inmunoterapeutico para la terapia de segunda linea contra carcinoma de vejiga urinaria.
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533818B1 (ko) * 1996-12-18 2005-12-07 스탠포드 룩 리미티드 면역계의 ｔｈ2 활성의 하향 조절을 위한 마이코박테리움 박케
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
DE602004028000D1 (de) * 2003-04-23 2010-08-19 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz

Also Published As

Publication number Publication date
PT1618128E (pt) 2010-10-13
CN1798762B (zh) 2010-04-28
AU2004232485B2 (en) 2009-11-26
HK1091217A1 (zh) 2007-01-12
CY1110793T1 (el) 2015-06-10
RU2005136354A (ru) 2006-03-20
CU23608A3 (es) 2010-12-08
WO2004094469A1 (en) 2004-11-04
EP1618128B1 (en) 2010-07-07
BRPI0409789B8 (pt) 2021-05-25
ATE473238T1 (de) 2010-07-15
MXPA05011360A (es) 2005-11-28
US20120027794A1 (en) 2012-02-02
EP1618128A1 (en) 2006-01-25
UA91180C2 (uk) 2010-07-12
JP4662925B2 (ja) 2011-03-30
US8545854B2 (en) 2013-10-01
PL1618128T3 (pl) 2010-12-31
US7988980B2 (en) 2011-08-02
KR20050114281A (ko) 2005-12-05
BRPI0409789B1 (pt) 2018-10-16
ZA200508276B (en) 2006-06-28
BRPI0409789A (pt) 2006-05-30
RU2342400C2 (ru) 2008-12-27
CA2523084C (en) 2012-09-04
JP2007524367A (ja) 2007-08-30
CN1798762A (zh) 2006-07-05
ES2344698T3 (es) 2010-09-03
CA2523084A1 (en) 2004-11-04
KR101101263B1 (ko) 2012-01-04
AU2004232485A1 (en) 2004-11-04
DE602004028000D1 (de) 2010-08-19
DK1618128T3 (da) 2010-10-18
SI1618128T1 (sl) 2010-11-30
US20070134267A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
HRP20100395T1 (hr) Cjepivo protiv tuberkuloze poboljšane učinkovitosti
US6855320B2 (en) Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
Dhama et al. DNA vaccines and their applications in veterinary practice: current perspectives
US7635479B2 (en) Composition and methods for enhancing immunogenecity of antigens
Al-Mariri et al. Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen
EP1537214B1 (en) Regulated bacterial lysis for gene vaccine vector delivery and antigen release
JP2001514000A5 (uk)
WO2011100754A1 (en) Live listeria-based vaccines for central nervous system therapy
Cassataro et al. Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting
Brockstedt et al. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies
Walcher et al. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors
Rashid et al. Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route
Martin et al. The combination of plasmid interleukin‐12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette–Guèrin) in protecting against systemic Mycobacterim avium infection
CA3202257A1 (en) Compositions and methods
US6471967B1 (en) Recombinant intracellular pathogen vaccines and methods for use
US9078844B2 (en) Combination of a bacterial cell and a biologically active agent
US7569552B2 (en) DNA vaccines against tumor growth and methods of use therof
Chaudhuri et al. Cloning of 87 k D a outer membrane protein gene of Pasteurella multocidaP 52
Liu Listeria-based anti-infective vaccine strategies
Cai et al. Immunogenicity and protective efficacy study using combination of four tuberculosis DNA vaccines
Shahzad et al. Evaluation of DNA vaccines encoding M. Tb gene Bfrb and Mpt32 in mice model
Portilho et al. Different Platforms, Immune Response Modulators and Challenges in SARS-CoV-2 Vaccination
Minassian et al. Tuberculosis vaccines: present and future
Derrick Recombinant Bacillus Calmette-Guérin for Mucosal Immunity
CN119931911A (zh) 一种重组rMS::MPT64及其应用